Economic impact of providing workplace influenza vaccination: A model and case study application at a Brazilian pharma-chemical company

PharmacoEconomics

Volumn 16, Issue 5 II, 1999, Pages 563-576

  Burckel, Emmanuel ^a   Ashraf, Talat ^b   Galvão De Sousa Filho, José P ^c   Neto, Eduardo Forleo ^a   Guarino, Hubert ^a   Yauti, Caio ^a   De Barreto, Fernando Barros ^c   Champion, Louis ^a  

^a R Do Rocio 351 10 Andar SP C   (Brazil)

^b Pharmaceutical Product Development   (United States)

^c Booz Allen and Hamilton do Brasil   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; BRAZIL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; OCCUPATIONAL HEALTH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BRAZIL; CHEMICAL INDUSTRY; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINATION; WORKPLACE;

EID: 0032718525     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916050-00012     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practice. (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45 (RR-5): 1-24
2. Monto AS, Koopman JS, Longini Jr IM, Tecumsch study of illness XII; influenza infection and disease, 1976-81. Am J Epidemiol 1985; 121: 811-22
3. Sullivan KM, Monto AS, Longini Jr IM. Estimates of the US health impact of influenza. Am J Public Health 1993; 83: 1712-6
4. LaForce FM, Nichol KL, Cox NJ. Influenza: virology, epidemiology, disease, and prevention. Am J Prev Med 1994; 10 Suppl.: 31-44
5. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1995; 44 (RR-3): 1-22
6. Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996, 9 Suppl. 3: 26-338
7. Institute of Medicine. New vaccine development: establishing priorities. Washington, DC: National Academy Press, 1985: 342-52
8. Gelzen WP, Six HR, Perrotta DM, et al. Epidemics and their causative viruses: community experience. In: Stuart-Harris C, Potter CW, editors. The molecular virology and epidemiology of influenza, London: Academic Press, 1984: 17-38
9. Glezen WP, Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4: 25-44
10. Prospects for immunizing against influenza viruses A and B. In: New vaccine development: establishing priorities. Washington, DC; National Academy Press, 1985: 342-64
11. Hall CE, Cooney MK, Fox JP. The Seattle virus watch: comparative epidemiologic observations of infections with influenza A and B viruses, 1965-1969, in families with young children. Am J Epidemiol 1973; 98: 365-80
12. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-93
13. Aymard M, Garcia A, Valette M, et al. Epidemiological study on the influenza virus in Latin America. In: Hannoun C, editor. Options for the control of influenza. II. Amsterdam: Excerpta Medica, 1993; 71-6
14. World Health Organization. Influenza activity during 1997-1998 season [online]. Available from: URL; http://www.who.int/emc /diseases/flu/countryprev.html
15. World Health Organisation. Influenza in the world. Wkly Epidemiol Rec 1998 Feb 13; 73 (7): 41-8
16. Merlin M, Buisson Y. L'evaluation de l'efficacite de la vaccination anti-grippale dans les armees au cours de l'hiver 89-90. Bull Epidemiol Hebd 1990; 41: 1975-6
17. Kilbourne ED. Inactivated influenza vaccines. In: Plotkin SA, Mortimer EA, editors. Vaccines. Philadelphia (PA): WB Saunders Co., 1994: 574
18. Monto AS, Ohmit SE, Foster DA, et al. Case-control study in Michigan on prevention of hospitalisation by vaccination, 1989-91. In: Hannoun C, editor. Options for the control of influenza II. Philadelphia (PA): Excerpta Medica, 1993: 135-41
19. Carrat F. Vaccination against influenza in healthy adults. New Engl J Med 1996; 334: 402-4
20. Kilbourne ED, Chanock RM, Choppin PW, et al. Influenza vaccine: summary of influenza workshop V. J Infect Dis 1974; 129: 770-1
21. Lévy E, Lévy P. La vaccination contre la grippe des personnes d'âge actif (25-64 ans): une étude coüt-bénéfice. Rev Epidem et Santé Publ 1992; 40; 285-95
22. Greenberg PE, Finkelstein SN, Berndt ER, et al. Calculating return on investment from reducing workplace illness. Drug Benefit Trends 1998; 10 (3): 44-7
23. Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 8-15
24. Mostow SR, Schoenbaum SC, Dowdle WR, et al. Studies on inactivated influenza vaccines II: effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol 1970; 92: 248-56
25. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 158: 205-8
26. Watson WH, Parks M, Porter DA, et al. Influenza vaccination in schoolboys. Lancet 1972; I: 1336
27. Mciklejohn G, Eickhoff TC, Graves P. Antigenic drift and efficacy of influenza virus vaccines, 1976-1977. J Infect Dis 1978; 5: 618-24
28. Champion L. Cost-benefit model for influenza vaccination in companies. Pasteur Mérieux Soros and Vacinas, Sao Paulo: Pasteur Mérieux Connaught, 1997, (data on file)
29. Greenberg PE, Finkelstein SN, Berndth ER. Economic consequences of illness in the workplace. Sloan Manage Rev 1995; 36 (4): 26-38